EFFICACY OF TELITACICEPT ON RENAL OUTCOMES IN PATIENTS WITH BIOPSY-PROVEN LUPUS NEPHRITIS

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/925172ac18ef387123a55c0e31c93fb5.pdf
EFFICACY OF TELITACICEPT ON RENAL OUTCOMES IN PATIENTS WITH BIOPSY-PROVEN LUPUS NEPHRITIS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Tingmin
Zhang
Tingmin Zhang zhangtm91@163.com The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China Department of Nephrology Hefei China *
Jun Jiang jiangjun1915@ustc.edu.cn The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China Department of Nephrology Hefei China -
Lei Lan lanlei1976@126.com The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China Department of Nephrology Hefei China -
 
 
 
 
 
 
 
 
 
 
 
 

To investigate the efficacy of Telitacicept in patients with biopsy-proven lupus nephritis.

This study enrolled twenty-one patients with biopsy-proven lupus nephritis who were treated with Telitacicept plus conventional therapy for at least 6 months. The laboratory test and renal remission rate were assessed during the follow-up period.

With a minimum follow-up of 12 months, all patients achieved partial or complete remission after 6-24 months’ treatment with Telitacicept. Significant improvements were observed at 3 months, including a decrease in the urinary protein to creatinine ratio (UPCR) and increases in serum albumin (ALB) and hemoglobin (Hb) levels. C3, C4 complement concentrations and platelet (PLT) were markedly elevated at 1 month, while immunoglobulins (IgG, IgA, and IgM) decreased significantly and remained at low levels over the following 12 months. Compared with the non-initial treatment group, patients initially treated with Telitacicept had significantly lower baseline albumin, C3, and C4 levels, but subsequent follow-up revealed no statistically significant differences between the groups.

Note: N (%). CR, complete response; PR, partial response; NR, no response; PEER, primary efficacy renal response. *This relapsed patient presented with progressively deteriorating renal function and severe baseline renal impairment (Scr 536 μmol/L). Complete remission of proteinuria and stable renal function were maintained during Telitacicept treatment, while proteinuria recurred following drug discontinuation.Figure 1 Changes of UPCR, ALB, Scr, immunoglobulin (IgG, IgA) and complement (C3 and C4) in the 21 patients with LN who received treatment with Telitacicept during the follow-up period. A, UPCR; B, ALB; C, Scr; D, IgG; E, IgA; F, C3; G, C4.Figure 2 Time to get remission(PR or CR) that is maintained through 24 months

Telitacicept is a promising treatment option for patients with LN. The study demonstrated favorable efficacy and safety in LN patients, regardless of whether they were undergoing initial therapy, had failed previous treatments, or had experienced disease relapse. We recommend immediate Telitacicept initiation upon LN diagnosis, particularly in high-risk subgroups with severe hypoalbuminemia and complement consumption.

Kewords